Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $14.83 Average Target Price from Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have received an average rating of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $16.7143.

KPTI has been the subject of a number of recent analyst reports. Cantor Fitzgerald began coverage on Karyopharm Therapeutics in a research report on Thursday, February 5th. They set an “overweight” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, February 18th. Piper Sandler reissued an “overweight” rating and issued a $12.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Finally, The Goldman Sachs Group set a $12.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th.

Institutional Trading of Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LLC acquired a new position in Karyopharm Therapeutics during the fourth quarter worth $74,000. T. Rowe Price Investment Management Inc. grew its stake in shares of Karyopharm Therapeutics by 112.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock valued at $10,977,000 after buying an additional 790,417 shares in the last quarter. Ikarian Capital LLC raised its holdings in shares of Karyopharm Therapeutics by 1,897.9% in the 4th quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock valued at $4,008,000 after buying an additional 517,297 shares during the period. Tudor Investment Corp ET AL purchased a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at $95,000. Finally, Quadrature Capital Ltd acquired a new position in Karyopharm Therapeutics during the 4th quarter worth about $439,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Performance

Shares of Karyopharm Therapeutics stock opened at $7.85 on Monday. The stock has a 50 day moving average of $7.86 and a 200 day moving average of $6.82. The firm has a market capitalization of $143.97 million, a price-to-earnings ratio of -0.47 and a beta of 0.13. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Friday, February 13th. The company reported ($2.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.03. The business had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $33.16 million. Analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current year.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.